Q2 2021 Results - Reimagining Medicine

Participants Financial performance Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations ZolgensmaⓇ - SMN1 gene replacement therapy Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milesstone(s) Publication NCT03505099 SPR1NT (CL-304) Spinal muscular atrophy Phase 3 30 [2 copies of SMN2] Percentage of participants achieving functional independent sitting for at least 30 seconds at any visit [3 copies of SMN2] Percentage of participants achieving the ability to stand without support for at least 3 seconds at any visit Open-label, single-arm, single-dose, intravenous Pre-symptomatic patients with spinal muscular atrophy and multiple copies SMN2 H2-2021 (3-copy cohort) Final study results of 2-copy cohort as late-breaker oral presentation at EAN Jun 22 2021 92 Investor Relations | Q2 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation